Abstract
Aims
Pulsed field ablation (PFA) is a ablation modality that is increasingly used for pulmonary vein isolation (PVI) in atrial fibrillation (AF) patients. This study assessed the safety and effectiveness of a balloon-based PFA system at 6 months after treatment.
Methods and results
This study is a prospective, single-center, premarket study. A total of 56 patients with drug-refractory paroxysmal atrial fibrillation (PAF) were enrolled between November 2024 and September 2025 and underwent PVI with a balloon-based PFA system. The study endpoints were the rate of primary serious adverse events, acute procedural effectiveness and 6-month freedom from recurrence. Acute effectiveness was achieved in 100% (231/231) of the treated PVs (100% of patients, 56/56), with 33 ± 5.5 PFA applications/patient. The procedure, fluoroscopy, and transpired ablation times were 89.0 ± 30.7, 24.2 ± 8.3, and 20.0 ± 12.0 min, respectively. One (1.8%; 1/56) primary serious adverse event occurred: one patient developed intraoperative gastrointestinal bleeding due to TEE-induced mechanical injury. One patient developed a cerebral infarction on postoperative Day 28. The rate of freedom from documented atrial arrhythmias was 92.9% through 6 months after the index procedure.
Conclusion
The primary results of this study demonstrate the safety and effectiveness of the balloon-based PFA system for performing PVI in patients with PAF.
Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1007/s10840-026-02417-4.
Keywords: Pulsed field ablation, Atrial fibrillation, Pulmonary vein isolation, Catheter ablation, Balloon-based
Background
Atrial fibrillation (AF) is a prevalent clinical cardiac arrhythmia characterized by chaotic atrial electrical activity leading to rapid and irregular atrial contractions. AF not only severely impairs patients’ quality of life but also causes severe complications, most prominently stroke, thromboembolism, and heart failure. Catheter ablation has become the first-line therapy for rhythm control in patients with AF [1, 2], with radiofrequency ablation (RFA) and cryoablation being the most widely used modalities. However, both conventional ablation approaches have inherent limitations: RFA is associated with significant intraoperative pain and thermal conduction-induced injury to adjacent structures (esophagus, phrenic nerve, and coronary arteries), leading to severe complications such as atrial–esophageal fistula; and cryoablation is associated with risks of phrenic nerve palsy, along with low ablation efficiency and a prolonged procedure duration [3, 4]. Thus, exploring safer, more effective, and efficient therapeutic strategies for AF has become a research hotspot in cardiovascular medicine.
Pulsed field ablation (PFA), an emerging ablation technology, is being increasingly applied in AF treatment. It ablates myocardial tissue via irreversible electroporation while preserving critical epicardial structures, including the esophagus and phrenic nerve [5–8]. Recent clinical studies have demonstrated its efficacy comparable to that of RFA and cryoablation, and consistent evidence confirms the superior safety of PFA systems, especially in reducing injury to adjacent organs caused by energy conduction [9–11]. However, with the expanding application of PFA in AF catheter ablation, challenges have emerged, including inadequate tissue contact accuracy and risks of severe hemolysis and renal failure. Given the differences in structural and waveform design among PFA systems, each new device requires a rigorous evaluation of these specific factors. This study aimed to assess the safety and feasibility of a balloon-based PFA system (EnChannel Medical) for the catheter ablation of paroxysmal AF.
Methods
A total of 56 patients with paroxysmal AF who underwent their first PFA treatment at TEDA International Cardiovascular Hospital from November 2024 to September 2025 were enrolled. The inclusion criteria were as follows: (1) aged 18–75 years, regardless of sex; (2) diagnosed with symptomatic paroxysmal AF (terminating spontaneously within 7 days of onset or with treatment, documented by electrocardiogram or ambulatory electrocardiography within 1 year before enrollment); (3) a poor response to or intolerance of at least one class I or III antiarrhythmic drug (AAD); and (4) willingness to comply with follow-up protocols and provide written informed consent. The key exclusion criteria were a left atrial (LA) diameter > 47 mm, New York Heart Association (NYHA) functional class III or IV, previous ablation therapy in the LA and the presence of any implantable cardiac devices (see the Supplementary material). All patients provided informed consent, and this study was approved by the Ethics Committee of TEDA International Cardiovascular Hospital ([2024]1018-2).
Preoperative preparations included transthoracic echocardiography for assessing cardiac structure and function; measurements of cardiac biomarkers, markers of liver/renal function, routine blood counts, and coagulation tests; pulmonary vein computed tomography angiography (CTA) within 48 h to clarify pulmonary vein morphology; and transesophageal echocardiography (TEE) to exclude left atrial/appendage thrombus. Routine anticoagulation with nonvitamin K antagonist oral anticoagulants (NOACs) was administered, with a 12-h withholding period preoperatively; patients fasted for 8 h preoperatively.
The investigational balloon PFA system consisted of a PFBalloon catheter (11 Fr shaft, 12 pairs of evenly distributed flexible electrodes on the balloon surface; EnChannel Medical, China; Fig. 1), a PFA generator (NanoAblate, EnChannel Medical, China; Fig. 1), and a 13 Fr deflectable sheath (Linkman, EnChannel Medical, China). The balloon was filled with a saline-contrast medium mixture for fluoroscopic visualization, ensuring adequate electrode‒tissue contact and minimizing blood pool exposure. PFA therapy was delivered as bipolar biphasic pulsed electric fields without R-wave-gated pulse sequences between consecutive electrode pairs. All procedures were performed under general anesthesia: two 6 F sheaths were implanted via the left femoral vein for a 10-pole coronary sinus (CS) electrode and a right ventricular electrode; transseptal puncture was performed via the right femoral vein, with immediate heparin sodium administration (1000 IU/kg) to maintain the activated clotting time (ACT) at 250–350 s. A multipolar mapping catheter was used to create a preablation three-dimensional geometry with voltage mapping of the LA (DePolar system, EnChannel Medical, China). The mapping catheter was then removed. The PFA catheter was advanced into the left atrium after air evacuation, and ablation was performed at the pulmonary vein antrum and ostium (left superior/inferior, right superior/inferior pulmonary veins). The balloon was fully inflated to achieve tight apposition for antral ablation; 2 applications were delivered at the initial position, followed by a 15° rotation for 2 additional applications (Figs. 2 and 3). The balloon was then partially deflated and advanced to the pulmonary vein ostium (forming a heart-shaped configuration), where two applications were delivered, followed by another 15° rotation for 2 additional applications (Figs. 2 and 3). Accordingly, the standard dosing protocol consisted of 8 applications per pulmonary vein. The ablation parameters were a bipolar, biphasic waveform on a microsecond scale of ± 750 V with one pulse per train and four pulse trains per application, including a 700-ms pause time between trains, totaling approximately 2.1 s per application. Pulmonary vein isolation was confirmed by bidirectional conduction block after a 20-min waiting period (Fig. 4), with additional energy delivery for residual connections if needed.
Fig. 1.

A, PF balloon catheter (11 Fr shaft, 12 pairs of evenly distributed flexible electrodes on the balloon surface; EnChannel Medical, China). B, PFA generator (NanoAblate, EnChannel Medical, China)
Fig. 2.

The pulmonary vein potential disappeared after ablation
Fig. 3.

A, The balloon was fully inflated to achieve tight apposition for antral ablation. B, The balloon was partially deflated and advanced to pulmonary vein ostium ablation (forming a heart-shaped configuration)
Fig. 4.

Postablation voltage map of the left atrium. The map shows acute pulmonary vein isolation. The gray areas represent ablated or electrically isolated tissue around the 4 pulmonary veins
Postoperatively, patients remained recumbent for 12 h and received routine antiarrhythmic and anticoagulant therapy consistent with RFA/cryoablation. Perioperative complications (puncture-related complications, bleeding, thromboembolism, phrenic nerve injury, cardiac tamponade, cerebral infarction, esophageal injury, and death) were monitored. Scheduled follow-up occurred at 30 days, 3 months and 6 months. Follow-up is ongoing and will be completed at the 12-month visit for all patients. A 90-day blanking period was observed after the index ablation procedure. Medication adjustments, cardioversions, and one repeated ablation procedure utilizing the PFBalloon system were allowed during the blanking period without being considered a failure to achieve the primary effectiveness endpoint. At 30 days, patients were reminded to discontinue antiarrhythmic drugs (AADs) unless clinically justified. Subjects must be off all class I and III AADs prescribed for AF/AFL/AT after the blanking period.
The primary safety endpoint was defined as the percentage of patients who experienced a predefined device and/or procedure-related serious adverse event with onset within 7 days of any ablation procedure (index or repeat procedure) in which the PFA system was used. The predefined primary safety events included the following: atrial–esophageal fistula, cardiac tamponade/perforation, death, myocardial infarction, pericarditis (only considered a primary safety endpoint event if it resulted in a pericardial effusion that leads to hemodynamic compromise, required pericardiocentesis, prolonged or required hospitalization for more than 48 h for reasons other than observational purposes, or persisted for more than 30 days following the ablation procedure), phrenic nerve injury resulting in permanent diaphragmatic paralysis, PV stenosis, stroke/cerebrovascular accident, thromboembolism, transient ischemic attack, major vascular access complications (defined as a complication that required intervention, such as surgical repair, vascular catheter intervention or thrombin injection, or prolonged the hospital stay or required hospital admission for reasons other than for observational purposes), or major bleeding events (considered a primary endpoint event if it required and/or was treated with transfusion or resulted in a 20% or greater decrease in hematocrit). Other adverse events considered reportable were events that were cardiovascular-related events or assessed by the investigator as being related to (including those possibly related to) either the ablation catheter or the ablation procedure and all serious adverse events, regardless of relatedness to the procedure and/or the ablation catheter.
A 12-lead electrocardiogram (ECG) was performed at the 30-day and 6-month visits. At 3 months, patients wore a Holter monitor for 24 h as part of the follow-up. Clinically significant AF recurrence was defined as documented AF, atrial flutter, or atrial arrhythmia lasting > 30 s.
Statistical analyses were performed with SPSS 22.0 (IBM Corp., Armonk, NY, USA). Normally distributed continuous variables are presented as the means ± standard deviations (x ± s), nonnormally distributed variables are presented as the medians (interquartile ranges), and categorical variables are presented as n (%). Paired t tests were used for preoperative‒postoperative comparisons of normally distributed variables. A two-sided P < 0.05 was considered to indicate statistical significance.
Results
A total of 56 patients (mean age 62.4 ± 8.7 years) underwent successful ablation with the investigational PFA system. The baseline characteristics included 67.8% males, a mean BMI of 26.3 ± 3.3 kg/m², a mean CHA₂DS₂-VA score of 1.5 ± 1.1, a mean LVEF of 63.1 ± 4.3%, and a mean left atrial diameter of 37.6 ± 3.6 mm; the most common comorbidities were hypertension (58.9%), coronary heart disease (37.5%), and diabetes (16.1%). Patients’ characteristics are summarized in Table 1.
Table 1.
Patient characteristics
| Patient Characteristic | (N=56) |
|---|---|
| Age (years) | 62.4±8.7 |
| Sex (male) | 38 (67.8%) |
| Body mass index (Kg/m2) | 26.3±3.3 |
| CHA2DS2VA score | 1.5±1.1 |
| LVEF | 63.1±4.3 |
| LA diameter | 37.6±3.6 |
| Cardiovascular History | |
| Coronary artery disease | 21 (37.5%) |
| Diabetes | 9 (16.1%) |
| Hypertension | 33 (58.9%) |
| Obstructive sleep apnea | 4 (7.1%) |
| Stroke/Transient ischemic attack | 6 (10.7%) |
The mean procedure duration was 89.0 ± 30.7 min, the mean fluoroscopy time was 24.2 ± 8.3 min, and the mean ablation time (first to last energy delivery) was 20.0 ± 12.0 min. The mean number of energy deliveries per patient was 33.0 ± 5.4, with 8.9 ± 3.4, 8.0 ± 0.1, 8.7 ± 1.8, and 8.1 ± 0.5 deliveries to the left superior vein, left inferior vein, right superior vein, and right inferior pulmonary vein, respectively. The procedural characteristics are summarized in Table 2.
Table 2.
Procedural characteristics
| Procedural characteristics | (N=56) |
|---|---|
| Procedure time (min) | 89.0 ± 30.7 |
| LA dwell time (min) | 57.0 ± 16.8 |
| Transpired ablation time (min) | 20.0 ± 12.0 |
| Fluoroscopy time (min) | 24.2 ± 8.3 |
| PFA applications/patient | 33.0 ± 5.4 |
| Left superior pulmonary veins | 8.9 ± 3.4 |
| Left inferior pulmonary veins | 8.0 ± 0.1 |
| Right superior pulmonary veins | 8.7 ± 1.8 |
| Right inferior pulmonary veins | 8.1 ± 0.5 |
LA left atrium. The total procedure time is defined as the time from the first venous puncture to the time when either groin sheath was pulled. The LA dwell time is defined as the time at which the PF balloon catheter entered the LA to the time at which the PF balloon catheter exited the LA. The transpired ablation time is defined as the time from the first application of PFA therapy to the last application of PFA therapy
In terms of efficacy, acute electrical isolation was achieved in all 231 pulmonary veins (100% success rate), with no acute reconnection observed. All the patients completed the 6-month follow-up, and 92.9% (52/56) of the patients were free from documented atrial arrhythmias and AADs. Four patients underwent repeat procedures, and 2 of the patients’ remaining PVs were isolated. The reasons for a failure to achieve the effectiveness endpoint are summarized in Table 3. Eight patients (14.3%, 8/56) used propafenone after the procedure. Four patients (7.1%, 4/56) underwent a repeat procedure involving propafenone/amiodarone after the blanking period (2 received propafenone; 2 received amiodarone), and other four patients discontinued antiarrhythmic drugs at the 30-day visits.
Table 3.
Reasons for a failure to achieve the effectiveness endpoint
| Patients 1 | Patients 2 | Patients 3 | Patients 4 | |
|---|---|---|---|---|
| Atrial arrhythmias | AFL | AFL | AFL | AT |
| The days since initial procedure | 70 | 71 | 70 | 84 |
| Subjects with repeat procedure and left atrial remapping | Yes | Yes | Yes | Yes |
| Originally isolated PV’s ablated with reconnections | Yes | Yes | No | No |
| Location of Reconnected Pulmonary Veins | LSPV | RSPV | None | None |
In terms of safety, one patient experienced an SAE (1.8%; 1/56) and developed intraoperative gastrointestinal bleeding due to TEE-induced mechanical injury to the esophagogastric fundal mucosa, which was successfully managed with hemostatic clipping. One patient who was administered 20 mg of rivaroxaban once daily postoperatively developed numbness in the head and face on postoperative Day 28. Brain magnetic resonance imaging (MRI) revealed multiple punctate infarcts. The patient’s neurological symptoms resolved with uninterrupted anticoagulant therapy. No death, cardiac tamponade, phrenic nerve injury, renal failure, or other PFA-related serious adverse events (SAEs) were observed. Perioperative laboratory tests showed mild, transient changes in the red blood cell count, hemoglobin level, and hematocrit (P < 0.05), with no statistically significant alterations in serum creatinine and urea levels (P > 0.05); total bilirubin and LDH levels were increased slightly at 1 day post-operatively (P = 0.0095), with no clinical jaundice. No clinically significant hemolysis was observed (Table 4).
Table 4.
Results of hematological and biochemical tests conducted before and after ablation (the data are presented as medians and interquartile ranges)
| Characteristic | Before procedure | After procedure immediately | P value (compared to before procedure) | After procedure 24h | P value (compared to before procedure) |
|---|---|---|---|---|---|
| RBC, k/mm3 | 4.7 ± 0.4 | 4.2 ± 0.4 | 0.0001 | 4.5 ± 0.4 | 0.0024 |
| Hb, g/L | 141.8 ± 11.6 | 125.1 ± 19.1 | 0.0001 | 134.9 ± 11.2 | 0.0009 |
| Ht, % | 42.4 ± 3.1 | 37.3 ± 5.5 | 0.0001 | 40.2 ± 2.9 | 0.0002 |
| Creatinine, umol/L | 65.8 ± 14.6 | 69.6 ± 15.4 | 0.1926 | 68.2 ± 14.5 | 0.3967 |
| Urea, mmol/L | 6.2 ± 1.5 | 5.6 ± 1.4 | 0.0294 | 5.7 ± 1.4 | 0.0705 |
| Total bilirubin, umol/L | 13.2 ± 5.8 | 14.9 ± 5.8 | 0.1041 | 18.9 ± 8.0 | 0.0001 |
| LDH, U/L | 165.2 ± 25.2 | 155.6 ± 26.1 | 0.0689 | 203.1 ± 23.1 | 0.0001 |
Continuous variables are shown as the means ± standard deviations (SDs) or medians and interquartile ranges (IQRs). Discrete variables are presented as numbers and percentages (%). The results of the hematological and biochemical tests conducted before and after the ablation procedure in the study population are shown as medians and interquartile ranges
Hb hemoglobin, Ht hematocrit, LDH lactate dehydrogenase, SD standard deviation, RBC red blood cell
Discussion
This single-center prospective exploratory study evaluated the safety and feasibility of a domestically developed balloon-based PFA system (EnChannel Medical) for catheter ablation of paroxysmal AF. The key findings are as follows: (1) the system achieved a 100% acute PVI success rate with no acute reconnection; (2) 92.9% of patients achieved 6-month freedom from clinically significant AF recurrence; (3) the system had a good safety profile with 1.8% of patients experiencing PFA-related severe complications; and (4) patients had low risks of hemolysis and renal injury, with mild and transient perioperative changes in hematological parameters. These results provide important clinical evidence for the safety and efficacy of this domestic PFA system, supporting its potential clinical application for paroxysmal AF.
Safety of the balloon-based PFA system
The most prominent advantage of PFA over conventional thermal ablation is its nonthermal irreversible electroporation mechanism, which selectively ablates myocardial tissue while preserving the structural and functional integrity of adjacent nonmyocardial tissues (esophagus, phrenic nerve, and coronary arteries) [12–14]. This fundamental advantage is the core reason for the low incidence of adjacent organ injury during PFA treatment. In this study, no phrenic nerve injury, esophageal injury, or atrial–esophageal fistula was observed, which is consistent with the results of previous PFA studies. The balloon-based “one-shot” ablation mode reduces the frequency of catheter manipulation in the left atrium, thereby lowering the risks of cardiac tamponade and other procedure-related complications. Notably, no cardiac tamponade occurred even with relatively low operator familiarity with this novel system, suggesting a low procedural risk and a short learning curve for electrophysiologists, which is an important advantage for clinical promotion [14].
Cerebral infarction occurred in one patient enrolled in the present study. This patient had a CHA₂DS₂-VA score of 3 and a medical history of hypertension; suboptimal blood pressure control was noted at the time of cerebral infarction onset. We postulate that the cerebral infarction was caused by the synergistic effects of a postoperative high thrombotic risk status and hypertension. For patients at high risk of ischemic complications, in addition to sustaining continuous anticoagulant therapy, comprehensive and optimized management of other risk factors predisposing the patient to ischemic events is warranted.
Hemolysis is a major potential safety concern of PFA, which is related mainly to energy delivery in the blood pool, the number of energy pulses released, and the degree of electrode‒tissue contact [15, 16]. Severe hemolysis may lead to acute renal failure, which has been reported in some PFA studies. In this study, the balloon-based catheter minimized electrode‒blood contact through tight tissue apposition, resulting in no clinically significant hemolysis. Perioperative laboratory tests revealed only mild changes in the red blood cell count, hemoglobin level, hematocrit, total bilirubin level and LDH level, with no significant alterations in the levels of indicators of renal function (creatinine level or urea level), indicating low risks of hemolysis and renal injury.
Efficacy of the balloon-based PFA system
Pulmonary vein isolation is the gold standard for AF catheter ablation, and the acute PVI success rate is a key indicator of ablation efficacy. In this study, the 100% acute PVI success rate is consistent with the results of other balloon-based PFA studies, which is mainly due to the advantages of a uniform electrode distribution and tight tissue contact when using the balloon catheter; these features ensure the complete ablation of pulmonary vein myocardial sleeves and avoid ablation gaps caused by inadequate electrode–tissue contact.
The finding that 92.9% of patients achieved 6-month freedom from clinical AF recurrence in this study differs from the results of previous large-scale PFA trials (66.2%–86.2%) [14, 17–20]. Several factors may contribute to this mid-term efficacy: (1) The follow-up rhythm monitoring protocol (12-lead ECG at 30 days and six months and a single 24-hour Holter monitor at three months) is substantially inferior to monitoring via implantable cardiac monitors (ICMs) or prolonged ambulatory recording. The resulting surveillance gap introduces a systematic bias toward the underestimation of atrial arrhythmia recurrence, particularly asymptomatic episodes. (2) The study population was strictly limited to patients with paroxysmal AF who had a relatively small left atrial diameter (mean diameter of 37.6 ± 3.6 mm) compared with contemporary ablation trials (29.5%–60.7% of patients with persistent AF, LA size of 40.6–43.3 mm) [14, 17–20], whose ablation prognosis is better than that of patients with persistent AF or a large left atrial diameter. (3) The short 6-month follow-up period may lead to an overestimation of efficacy, and long-term follow-up (≥ 1 year) is needed to confirm chronic efficacy. (4) The small sample size of this exploratory study may also contribute to the high AF-free survival rate, and large-sample multicenter studies are needed for validation.
Limitations of this study
This study has several limitations that should be noted when interpreting the results. First, this exploratory single-center study only enrolled 56 patients, which may limit the generalizability of the results. Rare complications (e.g., atrial–esophageal fistula and coronary artery spasm) could not be effectively evaluated because of the small sample size. Second, efficacy and safety were only evaluated at 6 months; long-term follow-up (≥ 1 year) is needed to confirm the chronic efficacy, PVI persistence, and long-term complication incidence. Third, no electrophysiological remapping was performed during follow-up to evaluate PVI persistence; AF recurrence was based only on noninvasive electrocardiographic monitoring, which may have led to an underestimation of the actual recurrence rate.
Conclusions
This balloon-based PFA system (EnChannel Medical) has an excellent safety profile and high feasibility for paroxysmal AF ablation, with no severe PFA energy-related complications. It achieves a 100% acute pulmonary vein isolation success rate and 92.9% of patients achieved 6-month freedom from clinically significant AF recurrence, indicating the reliable acute and short-term chronic efficacy of this system. Long-term follow-up and multicenter randomized controlled trials are warranted to further validate its long-term efficacy and safety and to compare it with other ablation modalities and PFA systems.
Supplementary Information
Below is the link to the electronic supplementary material.
Acknowledgements
This work was supported by the Science Foundation of Tianjin Binhai New Area Health Commission (Grant No. 2023BWKQ012) and the Tianjin Key Medical Discipline Construction Project (Grant No. TJYXZDXK-3–035 C).
Author contributions
PZ W wrote the main manuscript text. JJ L designed the study. K Z and JL B finished the procedure. XH D, S Y, LC T and ZZ Q contributed to data collection, data analyses. Z L and YH M contributed to interpretation. All authors reviewed the manuscript.
Data availability
The data that support the findings are available from the corresponding author upon reasonable request.
Declarations
Disclosure
This study of the balloon-based PFA system was sponsored by EnChannel Medical.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the diagnosis and management of atrial fibrillation: a report of the american college of cardiology/American heart association joint committee on clinical practice guidelines[J]. Circulation. 2024;149(1):e1–156. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Tzeis S, Gerstenfeld EP, Kalman J, et al. 2024 European HeartRhythm Association/Heart Rhythm Society/Asia Pacific HeartRhythm Society/Latin American Heart Rhythm Society Expert consensus statement on catheter and surgical ablation of atrial fibrillation[J]. J Interv Card Electrophysiol. 2024;67(5):921–1072. [DOI] [PubMed] [Google Scholar]
- 3.Heeger CH, Sohns C, Pott A, Metzner A, Inaba O, Straube F, et al. Phrenic nerve injury during cryoballoon-based pulmonary vein isolation: results of the worldwide YETI registry. Circ Arrhythm Electrophysiol. 2022;15:e010516. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Tilz RR, Schmidt V, Pürerfellner H, Maury P, Chun K, Martinek M, et al. A worldwide survey on incidence, management, and prognosis of oesophageal fistula formation following atrial fibrillation catheter ablation: the POTTER-AF study. Eur Heart J. 2023;44:2458–69. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Neumcke B, Walz D, Lauger P. Nonlinear electrical effects in lipid bilayer membranes. 3. The dissociation field effect[ J ]. Biophys J. 1970;10(2):172–82. [DOI] [PMC free article] [PubMed]
- 6.Benz R, Beckers F, Zimmermann U. Reversible electricalbreakdown of lipid bilayer membranes: a charge-pulse relaxationstudy. J Membr Biol. 1979;48(2):181–204. 10.1007/BF01872858. [DOI] [PubMed] [Google Scholar]
- 7.Chang DC. Cell poration and cell fusion using an oscillating electricfield. Biophys J. 1989;56(4):641–52. 10.1016/S0006-3495(89)82711-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Chang DC, Reese TS. Changes in membrane structure induced byelectroporation as revealed by rapid-freezing electron microscopy[J]. Biophys J. 1990;58(1):1–12. 10.1016/S0006-3495(90)82348-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Ekanem E, Neuzil P, Reichlin T, Kautzner J, van der Voort P, Jais P, et al. Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17 K study. Nat Med. 2024;30:2020–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Schmidt B, Bordignon S, Neven K, Reichlin T, Blaauw Y, Hansen J, et al. European real- world outcomes with pulsed field ablation in patients with symptomatic atrial fibrillation: lessons from the multi-centre EU-PORIA registry. Europace. 2023. 10.1093/europace/euad185. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Boersma L, Andrade JG, Betts T, Duytschaever M, Pürerfellner H, Santoro F, et al. Progress in atrial fibrillation ablation during 25 years of europace journal. Europace. 2023. 10.1093/europace/euad244. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Kamel O, Sawalha K, Abdelazem M, Abdelghany A, Elsaid M, Sharief M, Ammar A. Outcomes of Pulsed Field Versus Cryoballoon Ablation in Atrial Fibrillation: A Comprehensive Systematic Review and Meta-Analysis. J Arrhythm. 2026;42(1):e70277. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Reddy VY, Gerstenfeld EP, Mountantonakis SE et al. Pulsed field ablation versus conventional thermal ablation for paroxysmal atrial fibrillation: 4-year outcomes in the ADVENT-LTO study. Nat Med (2026). [DOI] [PMC free article] [PubMed]
- 14.Tilz RR, Chierchia GB, Gunawardene M, Sanders P, Haqqani H, Kalman J, Healy S, Pürerfellner H, Neuzil P, Asensi JO, Loh P, Reddy VY, Knecht S, Jesser E, Dirckx N, Miller A, Walker D, Lakkireddy D. Safety and effectiveness of the first balloon-in-basket pulsed field ablation system for the treatment of atrial fibrillation: VOLT CE Mark Study 6-month results. Europace. 2025;27(4):euaf072. [DOI] [PMC free article] [PubMed]
- 15.Popa MA, Venier S, Menè R, Della Rocca DG, Sacher F, Derval N, et al. Characterization and clinical significance of hemolysis after pulsed field ablation for atrial fibrillation: results of a multicenter analysis. Circ Arrhythm Electrophysiol. 2024;17:e012732. [DOI] [PubMed] [Google Scholar]
- 16.Mercado Montoya M, Gomez Bustamante T, Jessen M, Kulstad E, Mickelsen S, Overzet L. Quantification of hemolysis rates from pulsed field ablation. Eur Heart J. 2024;45:ehae666387. [Google Scholar]
- 17.Reddy VY, Gerstenfeld EP, Natale A, Whang W, Cuoco FA, Patel C, et al. Pulsed field or conventional thermal ablation for paroxysmal atrial fibrillation. N Engl J Med. 2023;389:1660–71. [DOI] [PubMed] [Google Scholar]
- 18.Verma A, Haines DE, Boersma LV, Sood N, Natale A, Marchlinski FE, et al. Pulsed field ablation for the treatment of atrial fibrillation: PULSED AF pivotal trial. Circulation. 2023;147:1422–32. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Reddy VY, Peichl P, Anter E, Rackauskas G, Petru J, Funasako M, et al. A focal ablation catheter toggling between radiofrequency and pulsed field energy to treat atrial fibrillation. JACC Clin Electrophysiol. 2023;9:1786–801. [DOI] [PubMed] [Google Scholar]
- 20.Turagam MK, Neuzil P, Schmidt B, Reichlin T, Neven K, Metzner A, et al. Safety and effectiveness of pulsed field ablation to treat atrial fibrillation: one-year outcomes from the MANIFEST-PF registry. Circulation. 2023;148:35–46. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The data that support the findings are available from the corresponding author upon reasonable request.
